Journal
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
Volume 25, Issue 1, Pages 22-35Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MED.0000000000000376
Keywords
carcinoid-syndrome; neuroendocrine tumor; peptide radioreceptor therapy; somatostatin; telotristat
Categories
Funding
- NIDDK of the NIH
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK053200] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Purpose of review To review recent advances and controversies in all aspects of carcinoid-syndrome. Recent findings Over the last few years there have been a number of advances in all aspects of carcinoid syndrome as well as new therapies. These include new studies on its epidemiology which demonstrate it is increasing in frequency; increasing insights into the pathogenesis of its various clinical manifestations and into its natural history: definition of prognostic factors; new methods to verify its presence; the development of new drugs to treat its various manifestations, both initially and in somatostatin-refractory cases; and an increased understanding of the pathogenesis, natural history and management of carcinoid heart disease. These advances have generated several controversies and these are also reviewed. Summary There have been numerous advances in all aspects of the carcinoid-syndrome, which is the most common functional syndrome neuroendocrine tumors produce. These advances are leading to new approaches to the management of these patients and in some cases to new controversies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available